WO2006133128A3 - INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN - Google Patents

INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN Download PDF

Info

Publication number
WO2006133128A3
WO2006133128A3 PCT/US2006/021807 US2006021807W WO2006133128A3 WO 2006133128 A3 WO2006133128 A3 WO 2006133128A3 US 2006021807 W US2006021807 W US 2006021807W WO 2006133128 A3 WO2006133128 A3 WO 2006133128A3
Authority
WO
WIPO (PCT)
Prior art keywords
epac
epsiv
phospholipase
plc
pld
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/021807
Other languages
French (fr)
Other versions
WO2006133128A2 (en
Inventor
Jon D Levine
Robert O Messing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to EP06772207A priority Critical patent/EP1896039A2/en
Publication of WO2006133128A2 publication Critical patent/WO2006133128A2/en
Anticipated expiration legal-status Critical
Publication of WO2006133128A3 publication Critical patent/WO2006133128A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides methods, compositions, and kits useful for reducing pain in a subject by inhibiting Epac, PLCϵ, and/or PLD. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that reduce pain. Methods of the invention can involve assaying test agent binding to Epac, PLCϵ, or PLD. Alternatively, test agents can be screened for their ability to alter the level of Epac, PLCϵ, or PLD polypeptides, polynucleotides, or action.
PCT/US2006/021807 2005-06-07 2006-06-05 INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN Ceased WO2006133128A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06772207A EP1896039A2 (en) 2005-06-07 2006-06-05 Inhibition of epac, phospholipase c ''epsilon'', and phospholipase d to treat pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68854605P 2005-06-07 2005-06-07
US60/688,546 2005-06-07

Publications (2)

Publication Number Publication Date
WO2006133128A2 WO2006133128A2 (en) 2006-12-14
WO2006133128A3 true WO2006133128A3 (en) 2008-08-07

Family

ID=37499022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021807 Ceased WO2006133128A2 (en) 2005-06-07 2006-06-05 INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN

Country Status (4)

Country Link
US (1) US20070060548A1 (en)
EP (1) EP1896039A2 (en)
CN (1) CN101378656A (en)
WO (1) WO2006133128A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006544A2 (en) * 2005-07-12 2007-01-18 Vrije Universiteit Brussel Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders
WO2011014622A1 (en) * 2009-07-31 2011-02-03 The Trustees Of Columbia University In The City Of New York Modulation of phospholipase d for the treatment of the acute and chronic effects of ethanol
KR101213070B1 (en) 2010-11-09 2012-12-18 부산대학교 산학협력단 Composition for Prevention or Treatment of Rheumatoid Arthritis Comprising the Phospholipase D1 inhibitor
JP6104896B2 (en) 2011-06-01 2017-03-29 アントフロゲネシス コーポレーション Treatment of pain using placental stem cells
US9751838B2 (en) 2012-10-02 2017-09-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tetrahydroquinoline derivatives and their use as Epac inhibitors
WO2014123680A1 (en) * 2013-02-08 2014-08-14 The Board Of Regents Of The University Of Texas System Antimicrobial methods using inhibitors of exchange proteins directly activated by camp (epac)
US9737512B2 (en) * 2015-03-11 2017-08-22 The Board Of Regents Of The University Of Texas System Methods and compositions for treating chronic pain
CN117503766B (en) * 2024-01-04 2024-04-26 中国康复研究中心 Application of PLD inhibitor in preparation of medicine for treating spinal cord injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519163A (en) * 1993-10-15 1996-05-21 Merck & Co., Inc. Inhibitors of phosphoinositide-specific phospholipase C
WO2003104250A1 (en) * 2002-06-07 2003-12-18 Kylix, B. V. New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519163A (en) * 1993-10-15 1996-05-21 Merck & Co., Inc. Inhibitors of phosphoinositide-specific phospholipase C
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
WO2003104250A1 (en) * 2002-06-07 2003-12-18 Kylix, B. V. New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)

Also Published As

Publication number Publication date
US20070060548A1 (en) 2007-03-15
WO2006133128A2 (en) 2006-12-14
CN101378656A (en) 2009-03-04
EP1896039A2 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
EP1858542A4 (en) COMPOSITIONS AND METHODS FOR TREATING VASCULAR PERMEABILITY
PL2500360T3 (en) Compositions and methods for diagnosing and treating cancer
ZA200901615B (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (en) Compositions and methods for diagnosing and treating cancer
EP1663259A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
WO2006083986A3 (en) Biomarkers for tissue status
EP1571968A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
EP1899480A4 (en) Compositions and methods for treating inflammatory conditions
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
EP1796666A4 (en) METHODS AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA
IL182061A0 (en) Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
ZA200708575B (en) Methods and compositions for treating or preventing cancer
WO2006024018A3 (en) Compositions for treating nociceptive pain
EP1578996A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
SI1771201T1 (en) Compositions and methods for treating or preventing oxalate-related disease
WO2010068918A3 (en) Novel targets for treatment of hypercholesterolemia
WO2008020942A3 (en) R-spondin compositions and methods of use thereof
EP1959931A4 (en) Compositions and methods for dermally treating pain
IL191237A0 (en) Compositions and methods for treating thrombocytopenia
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
WO2006133128A3 (en) INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN
PL2046341T3 (en) Compositions and methods for treating diabetes and neuropsychological dysfunction
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
EP2476681A3 (en) Amino-aza-adamantane derivatives and methods of use
WO2005089737A3 (en) Materials and methods for inhibiting wip1

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680027934.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006772207

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 91/CHENP/2008

Country of ref document: IN